NO942033D0 - Preparat omfattende koagulasjonsfaktor VIII, fremgangsmåte for fremstilling derav samt anvendelse av et overflateaktivt middel som stabilisator - Google Patents

Preparat omfattende koagulasjonsfaktor VIII, fremgangsmåte for fremstilling derav samt anvendelse av et overflateaktivt middel som stabilisator

Info

Publication number
NO942033D0
NO942033D0 NO942033A NO942033A NO942033D0 NO 942033 D0 NO942033 D0 NO 942033D0 NO 942033 A NO942033 A NO 942033A NO 942033 A NO942033 A NO 942033A NO 942033 D0 NO942033 D0 NO 942033D0
Authority
NO
Norway
Prior art keywords
preparation
stabilizer
surfactant
factor viii
coagulation factor
Prior art date
Application number
NO942033A
Other languages
English (en)
Norwegian (no)
Other versions
NO942033L (no
Inventor
Thomas Osterberg
Angelica Fatouros
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9202878A external-priority patent/SE9202878D0/xx
Priority claimed from SE9301580A external-priority patent/SE9301580D0/xx
Priority claimed from SE9302006A external-priority patent/SE9302006D0/xx
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of NO942033D0 publication Critical patent/NO942033D0/no
Publication of NO942033L publication Critical patent/NO942033L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO942033A 1992-10-02 1994-06-01 Preparat omfattende koagulasjonsfaktor VIII, fremgangsmåte for fremstilling derav samt anvendelse av et overflateaktivt middel som stabilisator NO942033L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9202878A SE9202878D0 (sv) 1992-10-02 1992-10-02 Protein formulation
SE9301580A SE9301580D0 (sv) 1993-05-07 1993-05-07 Protein formulation
SE9302006A SE9302006D0 (sv) 1992-10-02 1993-06-11 Protein formulation
PCT/SE1993/000793 WO1994007510A1 (fr) 1992-10-02 1993-10-01 Composition comprenant une formulation d'un facteur de coagulation viii, procede pour sa preparation et utilisation d'un agent tensioactif comme stabilisateur

Publications (2)

Publication Number Publication Date
NO942033D0 true NO942033D0 (no) 1994-06-01
NO942033L NO942033L (no) 1994-06-01

Family

ID=27355693

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942033A NO942033L (no) 1992-10-02 1994-06-01 Preparat omfattende koagulasjonsfaktor VIII, fremgangsmåte for fremstilling derav samt anvendelse av et overflateaktivt middel som stabilisator

Country Status (19)

Country Link
US (2) US5733873A (fr)
EP (3) EP1016673B1 (fr)
JP (1) JP3905921B2 (fr)
KR (1) KR100303872B1 (fr)
AT (2) ATE316981T1 (fr)
CA (1) CA2124690C (fr)
CZ (1) CZ290342B6 (fr)
DE (2) DE69329795T2 (fr)
DK (1) DK0627924T3 (fr)
ES (1) ES2154650T3 (fr)
FI (1) FI111443B (fr)
GR (1) GR3035472T3 (fr)
HU (2) HU220194B (fr)
MX (1) MX9306133A (fr)
NO (1) NO942033L (fr)
NZ (1) NZ256921A (fr)
PT (1) PT627924E (fr)
SK (1) SK282483B6 (fr)
WO (1) WO1994007510A1 (fr)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1016673B1 (fr) * 1992-10-02 2006-02-01 Genetics Institute, LLC Composition comprenant une formulation d'un facteur de coagulation VIII, procédé pour sa préparation et utilisation d'un agent tensioactif comme stabilisateur
SE504074C2 (sv) † 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6242417B1 (en) * 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5514781A (en) * 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP0852951A1 (fr) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
CA2362927C (fr) 1999-02-22 2011-07-12 University Of Connecticut Nouvelles formulations de facteur viii sans albumine
US20060099685A1 (en) * 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
DK1194161T3 (da) 1999-07-13 2006-02-13 Biovitrum Ab Stabile faktor VIII-sammensatninger
US6413537B1 (en) * 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
WO2004055164A2 (fr) * 2002-12-13 2004-07-01 Abgenix, Inc. Systeme et methode de stabilisation d'anticorps au moyen d'histidine
EP2289547B1 (fr) 2003-09-12 2015-12-16 Agenus Inc. Vaccin pour le traitement et la prévention de l'infection par le virus herpès simplex
WO2005107776A1 (fr) 2004-05-03 2005-11-17 Emory University Methode d'administration de facteur viii sans domaine b porcin
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
NO20210454A1 (no) 2004-11-12 2007-06-27 Bayer Healthcare Llc Setedirigert modifikasjon av FVIII
JP5022231B2 (ja) 2004-12-27 2012-09-12 バクスター・インターナショナル・インコーポレイテッド ポリマー−フォンビルブラント因子結合体
EP1877037A2 (fr) 2005-04-28 2008-01-16 Novo Nordisk Health Care AG Contenant ferme renfermant un polypeptide de facteur vii active, processus de preparation dudit contenant, kit associe, et procede d'utilisation dudit kit
ES2393117T3 (es) 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Composición farmacéutica estable que comprende una pirimidina-sulfamida
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7683158B2 (en) * 2006-03-31 2010-03-23 Baxter International Inc. Pegylated factor VIII
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CN103804489A (zh) 2006-12-15 2014-05-21 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
KR20150103333A (ko) 2007-04-26 2015-09-09 바이엘 헬스케어 엘엘씨 냉동 저장을 위한, 재조합 단백질의 액상 용액의 안정화
PL2235197T3 (pl) 2007-12-27 2018-01-31 Baxalta GmbH Sposoby hodowli komórek
EP2113564A1 (fr) * 2008-05-01 2009-11-04 Arecor Limited Formule pour protéines
US9120873B2 (en) 2008-08-21 2015-09-01 Octapharma Ag Recombinantly produced human factor VIII and IX
CA2735376C (fr) * 2008-09-03 2016-11-29 Octapharma Ag Nouvelles compositions protectrices pour le facteur viii produit de facon recombinante
EP2349341B1 (fr) * 2008-10-15 2013-10-09 Baxter Healthcare SA Pégylation de facteurs de coagulation sanguine recombinants en présence d'anticorps liés
JP5779780B2 (ja) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｖｉｉｉ因子製剤
KR101753242B1 (ko) 2008-12-31 2017-07-20 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
HUE037163T2 (hu) 2009-06-09 2018-08-28 Prolong Pharmaceuticals Llc Hemoglobin készítmények
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
MX366344B (es) 2009-06-25 2019-07-05 Revance Therapeutics Inc Formulaciones de toxina botulinica libres de albumina.
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
CN102573920B (zh) 2009-07-27 2015-01-14 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
DK2459224T3 (en) * 2009-07-27 2016-07-25 Baxalta GmbH Blodstørkningsproteinkonjugater
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
WO2011075185A1 (fr) 2009-12-18 2011-06-23 Oligasis Conjugués de polymère de phosphorylcholine à médicament ciblé
EA201691292A1 (ru) 2010-07-30 2017-08-31 Баксалта Инкорпорейтид Нуклеофильные катализаторы для оксимного связывания
KR101948337B1 (ko) 2010-11-05 2019-02-14 박스알타 인코퍼레이티드 증가된 특이 활성도를 갖는 항혈우병 인자 ｖｉｉｉ의 신규 변이체
WO2012082933A1 (fr) 2010-12-15 2012-06-21 Baxter International, Inc. Récupération d'éluat par utilisation d'un gradient de conductivité
CA2821945A1 (fr) * 2010-12-16 2012-06-21 Novo Nordisk A/S Solution aqueuse de facteur viii
CA2822591C (fr) 2010-12-22 2020-12-29 Baxter International Inc. Materiels et methodes pour la conjugaison d'un derive d'acide gras soluble dans l'eau a une proteine
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
US9212357B2 (en) 2012-12-03 2015-12-15 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof
SG10201707600XA (en) 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
EP3666283B1 (fr) * 2013-03-15 2022-06-08 Bioverativ Therapeutics Inc. Formulations de polypeptide de facteur viii
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3760639A1 (fr) 2013-09-08 2021-01-06 Kodiak Sciences Inc. Conjugués polymère zwittérionique
NZ722391A (en) 2014-02-04 2022-12-23 Biogen Ma Inc Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
JP7058940B2 (ja) * 2014-03-24 2022-04-25 バイオベラティブ セラピューティクス インコーポレイテッド 凍結乾燥第ｉｘ因子製剤
AU2015240354A1 (en) * 2014-04-01 2016-11-17 Advantech Bioscience Farmaceutica Ltda. Stabilization of Factor VIII without calcium as an excipient
US9907835B2 (en) 2014-04-01 2018-03-06 Advanced Bioscience Farmacêutica LTDA Stable Factor VIII formulations with low sugar-glycine
EP3193911B1 (fr) * 2014-07-25 2023-09-06 CSL Behring GmbH Préparations de facteur viii améliorées pour l'utilisation dans le traitement de l'hémophilie a
ES2788870T3 (es) * 2014-08-04 2020-10-23 Csl Ltd Formulación de factor VIII
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EP3294324A1 (fr) 2015-05-13 2018-03-21 Agenus Inc. Vaccins pour le traitement et la prévention du cancer
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
BR112018008319A2 (pt) * 2015-11-05 2018-10-30 Novo Nordisk A/S formulação de fviii
EP3167877A1 (fr) 2015-11-12 2017-05-17 Bayer Pharma Aktiengesellschaft Procédé de production de granules lyophilisés comprenant le facteur viii
SG11201804666QA (en) 2015-12-03 2018-06-28 Baxalta Inc Factor viii with extended half-life and reduced ligand-binding properties
CN111295094A (zh) 2017-10-09 2020-06-16 泰尔茂比司特生物技术有限公司 冻干容器及使用冻干容器的方法
TW202012430A (zh) 2018-04-26 2020-04-01 美商艾吉納斯公司 熱休克蛋白質－結合之胜肽組成物及其使用方法
JP2022525742A (ja) 2019-03-14 2022-05-19 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥用ローディングトレイ組立体及びシステム
WO2021001522A1 (fr) 2019-07-04 2021-01-07 CSL Behring Lengnau AG Facteur de von willebrand (vwf) tronqué pour augmenter la stabilité in vitro du facteur viii de coagulation
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2022014410A (es) * 2020-05-22 2022-12-06 R Pharm Overseas Inc INHIBIDOR DE IL-1ß DERIVADO DE IL1-R1 Y USO DEL MISMO.
WO2022099223A2 (fr) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Limited Purification de fviii à partir du plasma au moyen d'une adsorption d'oxyde de silicium
WO2022271962A1 (fr) * 2021-06-23 2022-12-29 Bioverativ Therapeutics Inc. Formulations de protéines chimériques du facteur viii et leurs utilisations
WO2023064886A1 (fr) * 2021-10-15 2023-04-20 Bioverativ Therapeutics Inc. Formulations de protéines chimériques du facteur viii et leurs utilisations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
EP0035204B2 (fr) * 1980-03-05 1991-05-22 Miles Inc. Compositions pasteurisées de protéines thérapeutiquement actives
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
CA1292686C (fr) * 1986-10-27 1991-12-03 Ze'ev Shaked Compositions pharmaceutiques d'interleukine-2 recombinante et procede de fabrication
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
EP0381345B1 (fr) * 1989-01-30 1994-07-13 Corint, Ltd. Composition aqueuse à base de desmopressine-CMC
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
EP1016673B1 (fr) * 1992-10-02 2006-02-01 Genetics Institute, LLC Composition comprenant une formulation d'un facteur de coagulation VIII, procédé pour sa préparation et utilisation d'un agent tensioactif comme stabilisateur

Also Published As

Publication number Publication date
SK282483B6 (sk) 2002-02-05
AU677797B2 (en) 1997-05-08
SK65994A3 (en) 1995-03-08
ES2154650T3 (es) 2001-04-16
DE69333974D1 (de) 2006-04-13
US5733873A (en) 1998-03-31
CA2124690C (fr) 2007-09-11
FI111443B (fi) 2003-07-31
JPH07501560A (ja) 1995-02-16
WO1994007510A1 (fr) 1994-04-14
GR3035472T3 (en) 2001-05-31
NZ256921A (en) 1996-05-28
FI942573A0 (fi) 1994-06-01
DE69333974T2 (de) 2006-08-03
EP1652534A2 (fr) 2006-05-03
AU5288393A (en) 1994-04-26
US5919766A (en) 1999-07-06
EP1652534A3 (fr) 2007-05-02
ATE198277T1 (de) 2001-01-15
HU9401382D0 (en) 1994-08-29
PT627924E (pt) 2001-05-31
JP3905921B2 (ja) 2007-04-18
EP0627924A1 (fr) 1994-12-14
CA2124690A1 (fr) 1994-04-14
ATE316981T1 (de) 2006-02-15
FI942573A (fi) 1994-06-01
HU211670A9 (en) 1995-12-28
MX9306133A (es) 1994-04-29
KR100303872B1 (ko) 2001-11-22
CZ290342B6 (cs) 2002-07-17
DE69329795T2 (de) 2001-07-05
EP1016673A1 (fr) 2000-07-05
HU220194B (hu) 2001-11-28
EP0627924B1 (fr) 2000-12-27
NO942033L (no) 1994-06-01
DK0627924T3 (da) 2001-04-30
CZ132894A3 (en) 1994-11-16
DE69329795D1 (de) 2001-02-01
HUT70330A (en) 1995-09-28
EP1016673B1 (fr) 2006-02-01

Similar Documents

Publication Publication Date Title
NO942033L (no) Preparat omfattende koagulasjonsfaktor VIII, fremgangsmåte for fremstilling derav samt anvendelse av et overflateaktivt middel som stabilisator
DE68922204D1 (de) Giessbare Sulfon-Peroxycarbonsäurezusammensetzung.
DE69133576D1 (de) Verfahren zur Herstellung von Enantiomerisch reine Beta-D-Dioxolan-Nukleoside
ATE311748T1 (de) Modifizierte formen des natamycins, verfahren zu ihrer herstellung und sie enthaltende antifungale zusammensetzungen
DE69317044D1 (de) Mittel zur regulierung vom hautfettigkeitsgrad
DE69431853T2 (de) Verfahren zur Herstellung von 1,1,3,3,3-Pentafluorpropen
ATE166881T1 (de) Verfahren zur herstellung von faktor viii
DE69504162D1 (de) Verfahren zur Herstellung von 2-Methyl-1,4-naphthochinon
BR9909841B1 (pt) derivados de pirazolinona, agente de controle de doenÇa das plantas, compostos de pirazolinona, processo para controlar doenÇas das plantas, e, uso dos derivados de pirazolinona.
DE59510180D1 (de) Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethyl-piperidin
DK0435177T3 (da) 4-Benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-oner samt deres anvendelse som antikonvulsive midler
ATE389010T1 (de) Verfahren zur herstellung von optisch aktiven pyridinethanol-derivaten
DE59301021D1 (de) Verfahren zur kontinuierlichen Herstellung von 3-Cyano-3,5,5-trimethylcyclohexanon.
DE69311220T2 (de) Verfahren zur Herstellung von 1,1,1,2-Tetrafluorethan
DE69810724T2 (de) Verwendung von Protein C Inhibitor zur Behandlung disseminierter intravasaler Gerinnung (DIC)
DE69412485D1 (de) Verfahren zur Herstellung von wässrigen Zusammensetzungen, die Persäuren enthalten
EE03171B1 (et) Hüübimistegur VIII vormi sisaldav kompositsioon, selle valmistamismeetod ning pindaktiivse aine kasutamine stabilisaatorina
ATE204853T1 (de) Schädlingsbekämpfungsmittel
ATE31917T1 (de) Verfahren zur herstellung von 3-(3,4dihydroxyphenyl)-serinen.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application